Technical Trend Overview
The stock’s technical trend has deteriorated from mildly bearish to outright bearish, reflecting growing selling pressure. The daily moving averages have turned bearish, indicating that short-term price action is weakening. This is corroborated by the Bollinger Bands, which show a mildly bearish stance on both weekly and monthly timeframes, suggesting increased volatility with a downward bias.
The Moving Average Convergence Divergence (MACD) presents a mixed picture: while the weekly MACD remains mildly bullish, the monthly MACD has turned bearish. This divergence implies that although short-term momentum may still hold some strength, the longer-term trend is weakening, signalling caution for investors with a longer horizon.
Momentum Indicators and Oscillators
The Relative Strength Index (RSI) on both weekly and monthly charts currently shows no clear signal, hovering in neutral territory. This suggests that the stock is neither overbought nor oversold, leaving room for further directional movement based on upcoming market catalysts.
The Know Sure Thing (KST) indicator echoes the MACD’s mixed signals, with a mildly bullish weekly reading but a bearish monthly outlook. This reinforces the notion of short-term resilience amid longer-term weakness.
Volume and Price Action
On-Balance Volume (OBV) analysis reveals a mildly bullish trend on the weekly scale, indicating that volume flow is somewhat supportive of price gains in the short term. However, the monthly OBV is bearish, signalling that over a longer period, selling volume has dominated. This volume divergence aligns with the mixed momentum signals and highlights the importance of monitoring volume trends closely.
Price-wise, Abbott India’s stock traded within a range of ₹26,160.00 to ₹26,814.95 on 9 July 2026, closing below the previous day’s close of ₹26,712.05. The 52-week high stands at ₹35,280.00, while the 52-week low is ₹25,164.00, placing the current price closer to the lower end of its annual range and underscoring recent weakness.
Momentum building strong! This Mid Cap from NBFC is on our MomentumNow radar. Other investors are catching on – will you join?
- - Building momentum strength
- - Investor interest growing
- - Limited time advantage
Comparative Performance Against Sensex
Abbott India’s recent returns present a nuanced picture when compared with the benchmark Sensex. Over the past week, the stock outperformed the Sensex with a 2.60% gain versus the index’s 0.54% decline. However, over the one-month period, Abbott India’s 1.71% gain lagged behind the Sensex’s 4.05% rise.
Year-to-date, the stock has declined by 9.76%, slightly outperforming the Sensex’s 10.23% fall. Over the past year, Abbott India’s performance has been weaker, with a 23.54% loss compared to the Sensex’s 8.61% decline. Longer-term returns tell a more positive story: over three years, Abbott India gained 11.71%, though this trails the Sensex’s 17.19% rise. Over five years, the stock outperformed with a 52.14% gain against the Sensex’s 45.53%, and over ten years, Abbott India’s return of 453.47% significantly surpassed the Sensex’s 182.02%.
Implications for Investors
The technical deterioration to a bearish trend, combined with mixed momentum signals, suggests that Abbott India is currently facing headwinds. The daily moving averages and monthly MACD bearishness indicate that the stock may continue to experience downward pressure in the near term. However, the mildly bullish weekly MACD and OBV readings hint at potential short-term support, which could offer tactical trading opportunities for nimble investors.
Given the stock’s proximity to its 52-week low and the neutral RSI readings, a decisive move either above key resistance levels or below support could set the tone for the coming weeks. Investors should watch for confirmation from volume trends and momentum oscillators before committing to new positions.
Abbott India Ltd. or something better? Our SwitchER feature analyzes this mid-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Mojo Score and Rating Update
MarketsMOJO’s latest assessment downgraded Abbott India from a Hold to a Sell rating on 12 May 2026, reflecting the deteriorating technical and fundamental outlook. The current Mojo Score stands at 37.0, signalling weak momentum and caution for investors. The mid-cap classification further emphasises the stock’s susceptibility to volatility and sector-specific risks within Pharmaceuticals & Biotechnology.
Investors should weigh these technical signals alongside broader market conditions and sector trends before making investment decisions. The pharmaceutical sector often faces regulatory and innovation-driven catalysts that can rapidly alter stock trajectories, making vigilant monitoring essential.
Conclusion
Abbott India Ltd. is currently navigating a challenging technical environment marked by a shift to bearish momentum and mixed indicator signals. While short-term oscillators and volume trends offer some optimism, the prevailing monthly bearishness and moving average weakness suggest caution. The stock’s recent underperformance relative to the Sensex over the past year contrasts with its strong long-term returns, underscoring the importance of a balanced, time-horizon sensitive approach.
For investors focused on mid-cap pharmaceutical stocks, Abbott India’s current technical profile warrants close attention, with potential opportunities arising from short-term momentum shifts but tempered by longer-term risks.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
